Morning Movers 03/20: (GMAN) (ECYT) (GALE) Higher; (TRGT) (DHT) (XXIA) Lower
Tweet Send to a Friend
Get Alerts TRGT Hot Sheet
Trade TRGT Now!
Targacept, Inc. (Nasdaq: TRGT) 24.7% LOWER; AstraZeneca (NYSE: AZN) and Targacept announced top-line results from the remaining Phase 3 studies investigating efficacy, tolerability and safety of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder who did not respond adequately to initial antidepressant treatment. RENAISSANCE 4 and RENAISSANCE 5, both efficacy and tolerability studies, did not meet the primary endpoint of change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score after eight weeks of adjunct treatment with TC-5214 as compared to placebo.
DHT Holdings (NYSE: DHT) 24.2% LOWER; registered to sell 51.785 million shares of common stock and 258,929 shares of Series A Participating Preferred Stock.
Gordmans Stores, Inc. (NASDAQ: GMAN) 17.6% HIGHER; reported Q4 EPS of $0.53, $0.03 better than the analyst estimate of $0.50. Revenue for the quarter came in at $185.1 million versus the consensus estimate of $186.11 million. Sees Q1 2012 EPS of $0.40-$0.41, versus the consensus of $0.40. Sees Q1 2012 revenue of $132-$133 million, versus the consensus of $128.9 million. Sees FY2012 EPS of $1.46-$1.51, versus the consensus of $1.48. Sees FY2012 revenue of $629-$634 million, versus the consensus of $622.6 million.
Endocyte (Nasdaq: ECYT) 15.9% HIGHER; after testing below the $5 level yesterday, shares have
Galena Biopharma, Inc. (Nasdaq: GALE) 14.8% HIGHER; today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering the use of its product candidate, NeuVax™, a HER2/neu peptide vaccine, for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC ratings of 1+ or 2+ and a FISH rating of less than about 2.0. These patients represent a significant unmet medical need, with as much as 50-75% of breast cancer patients who do not qualify for Herceptin® therapy.
Delcath Systems, Inc. (Nasdaq: DCTH) 12% HIGHER; has received the first commercial order for the Company's Hepatic CHEMOSAT Delivery System from the European Institute of Oncology (Instituto Europeo di Oncologia – IEO) –a premier cancer treatment and research center in Europe. Delcath previously announced an initial launch and training agreement with the IEO on November 21, 2011.
Ixia (Nasdaq: XXIA) 11.5% LOWER; announced that Victor Alston has been appointed as Ixia's Chief Operating Officer and will stand for election to the Board of Directors at the Company's annual meeting of shareholders scheduled to be held on May 10, 2012. In addition, the Company announced that Atul Bhatnagar, the Company's President and CEO, will be leaving the Company effective as of the date of the annual meeting and will not stand for reelection to the Board. The stock was downgraded at Wunderlich earlier.
Overseas Shipholding (NYSE: OSG) 10% LOWER; trading lower with most of the dry bulk shipping sector.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
DHT Holdings (NYSE: DHT) 24.2% LOWER; registered to sell 51.785 million shares of common stock and 258,929 shares of Series A Participating Preferred Stock.
Gordmans Stores, Inc. (NASDAQ: GMAN) 17.6% HIGHER; reported Q4 EPS of $0.53, $0.03 better than the analyst estimate of $0.50. Revenue for the quarter came in at $185.1 million versus the consensus estimate of $186.11 million. Sees Q1 2012 EPS of $0.40-$0.41, versus the consensus of $0.40. Sees Q1 2012 revenue of $132-$133 million, versus the consensus of $128.9 million. Sees FY2012 EPS of $1.46-$1.51, versus the consensus of $1.48. Sees FY2012 revenue of $629-$634 million, versus the consensus of $622.6 million.
Endocyte (Nasdaq: ECYT) 15.9% HIGHER; after testing below the $5 level yesterday, shares have
Galena Biopharma, Inc. (Nasdaq: GALE) 14.8% HIGHER; today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering the use of its product candidate, NeuVax™, a HER2/neu peptide vaccine, for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC ratings of 1+ or 2+ and a FISH rating of less than about 2.0. These patients represent a significant unmet medical need, with as much as 50-75% of breast cancer patients who do not qualify for Herceptin® therapy.
Delcath Systems, Inc. (Nasdaq: DCTH) 12% HIGHER; has received the first commercial order for the Company's Hepatic CHEMOSAT Delivery System from the European Institute of Oncology (Instituto Europeo di Oncologia – IEO) –a premier cancer treatment and research center in Europe. Delcath previously announced an initial launch and training agreement with the IEO on November 21, 2011.
Ixia (Nasdaq: XXIA) 11.5% LOWER; announced that Victor Alston has been appointed as Ixia's Chief Operating Officer and will stand for election to the Board of Directors at the Company's annual meeting of shareholders scheduled to be held on May 10, 2012. In addition, the Company announced that Atul Bhatnagar, the Company's President and CEO, will be leaving the Company effective as of the date of the annual meeting and will not stand for reelection to the Board. The stock was downgraded at Wunderlich earlier.
Overseas Shipholding (NYSE: OSG) 10% LOWER; trading lower with most of the dry bulk shipping sector.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Tesla (TSLA) Ramps Higher (GM)
- Streetinsider.com's Hot Lunchtime Reads 06/19: (NOK) (MW) (HLF) (VRNG) (YUM)
- Market Wrap: Housing Starts Lag Permits; Icahn Modifies Dell Bid; Takeover Chatter Hits Nokia
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Morning Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
